Charlotte A. Haslund

Aalborg, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Journal: Gynecologic oncology

Published: April 12, 2026

The role of socioeconomic position in use of systemic anticancer therapy.

The role of socioeconomic position in use of systemic anticancer therapy.

Journal: ESMO real world data and digital oncology

Published: April 10, 2026

Dose-enhanced versus standard TTFields for first recurrence of glioblastoma: A randomized phase 2 clinical trial.

Dose-enhanced versus standard TTFields for first recurrence of glioblastoma: A randomized phase 2 clinical trial.

Journal: Neuro-oncology advances

Published: July 23, 2025

Exploring survival-associated transcriptomic subtypes in ovarian cancer using RNAseq from FFPE tissues in a clinical trial cohort.

Exploring survival-associated transcriptomic subtypes in ovarian cancer using RNAseq from FFPE tissues in a clinical trial cohort.

Journal: Translational oncology

Published: May 24, 2025

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.

Journal: British journal of cancer

Published: February 12, 2025

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 22, 2025

ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.

ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.

Journal: Gynecologic oncology

Published: January 11, 2025

Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022).

Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022).

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 04, 2024

Mixed effect model confirms increased risk of image changes with increasing linear energy transfer in proton therapy of gliomas.

Mixed effect model confirms increased risk of image changes with increasing linear energy transfer in proton therapy of gliomas.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: September 11, 2024

Longer survival with precision medicine in late-stage cancer patients.

Longer survival with precision medicine in late-stage cancer patients.

Journal: ESMO open

Published: August 23, 2024

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 29, 2024

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome.

Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcome.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 18, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026